Neurology

CLN13 Disease (Kufs Disease Type B): A Patient Guide

At a Glance

CLN13 disease, also called Kufs disease type B, is a rare adult-onset form of Batten disease caused most often by CTSF gene variants. It progressively affects behavior, memory, thinking, and movement; genetic testing supports diagnosis, while care focuses on symptoms, function, and comfort.

CLN13, also known clinically as Kufs disease type B, is an exceptionally rare, adult-onset form of neuronal ceroid lipofuscinosis (NCL), a group of conditions often referred to as Batten disease ^[1]. Unlike childhood forms of NCL, CLN13 typically begins in adulthood, with symptom onset generally reported between the ages of 20 and 50. It is characterized by a “diagnostic odyssey” where early symptoms are often mistaken for more common neurological or psychiatric conditions ^[2]^[3]. It is most frequently caused by pathogenic (disease-causing) variants in the CTSF gene, which leads to a deficiency in the cathepsin F enzyme ^[4]. This deficiency prevents brain cells from properly recycling waste, resulting in the toxic buildup of materials called ceroid and lipofuscin that eventually leads to progressive nerve cell damage ^[4]^[1].

The disease behaves as a progressive neurodegenerative disorder, primarily affecting cognitive function and physical movement ^[1]. Early signs often involve “frontal” behavioral changes—such as shifts in personality, judgment, or social conduct—alongside gradual memory loss that may mimic early-onset dementia ^[2]^[3]. Over time, these cognitive changes are often joined by motor symptoms, which may include tremors, stiffness (parkinsonism), and a loss of coordination (ataxia) ^[2]^[5]. Notably, individuals with CLN13 often have relatively preserved vision. While this is not an absolute rule, it is a supportive clue that helps distinguish this adult-onset type from most childhood versions of Batten disease ^[6].

Accurate diagnosis has evolved significantly, moving away from tissue biopsies—which can be inconclusive or misleading in adults due to normal age-related changes—toward comprehensive molecular genetic testing ^[7]^[4]. Identifying the specific CTSF variants is crucial not only for confirming the disease but also for understanding its autosomal recessive inheritance and the implications for other family members ^[7]^[8]. Because there is currently no approved disease-modifying therapy for CLN13, management focuses on a multidisciplinary approach where specialists in neurology, therapy, and palliative care work together to treat symptoms and maintain the best possible quality of life ^[9]^[10].

Living with CLN13 requires adapting to change and balancing daily function with comfort and long-term planning ^[10]. As the disease progresses, the focus of care becomes more specialized, addressing complex needs like swallowing difficulties and mobility changes ^[11]^[12]. Integrating palliative care early in the process provides a roadmap for navigating these changes, ensuring that the person’s dignity, agency, and comfort remain at the center of every decision ^[13]^[9]. Through proactive management and a strong support network, patients and families can navigate the challenges of this rare condition together ^[14]^[15].

In this guide

6 chapters

Understanding CLN13 Disease

Learn what CLN13 disease is, how pathogenic CTSF variants cause adult-onset Batten disease, symptoms, diagnosis, progression, and supportive care for families.

Symptoms and Disease Progression

Learn about CLN13 symptoms and progression, including behavior changes, movement problems, seizures, swallowing concerns, and late-stage care needs over time.

Diagnostic Testing and the CTSF Gene

Learn how CLN13 is diagnosed through CTSF gene testing, variant interpretation, biopsy limits, autosomal recessive inheritance, and genetic counseling for families.

Misdiagnoses and Related Conditions

Learn why CLN13 can resemble Alzheimer’s, FTD, Parkinson’s disease, or psychiatric illness, and how genetic testing identifies the specific Kufs disease type.

Care, Management, and Symptom Relief

Learn how CLN13 disease care focuses on symptom relief, safe mobility, seizure planning, swallowing support, palliative care, and urgent warning signs to watch.

Daily Life, Caregiving, and Long-Term Planning

Learn how to support daily life with CLN13, manage behavior and safety changes, plan advance care, and find respite, therapy, and support for caregivers.

Common questions in this guide

What is CLN13 disease or Kufs disease type B?

CLN13 disease, also called Kufs disease type B, is a very rare form of neuronal ceroid lipofuscinosis that usually begins in adulthood. It gradually damages nerve cells and can affect behavior, memory, thinking, movement, and coordination. Vision is often relatively preserved compared with childhood forms.

What symptoms are common in CLN13 disease?

Early symptoms may include personality or behavior changes, poor judgment, changes in social conduct, and progressive memory loss. Later, people may develop tremors, stiffness or Parkinson-like movement, loss of coordination, swallowing problems, and reduced mobility. Vision often remains relatively preserved, although this is not universal.

How is CLN13 disease diagnosed?

A comprehensive molecular genetic test is the main way to confirm CLN13 disease by looking for disease-causing variants in the CTSF gene. Tissue biopsy is no longer the preferred approach because adult results can be inconclusive or confused with normal age-related changes. A genetics professional can explain what the result means for the patient and relatives.

Is CLN13 disease inherited in families?

Yes. CLN13 disease is usually inherited in an autosomal recessive pattern, which means a person generally has disease-causing CTSF variants in both gene copies. Genetic counseling can help relatives understand their chances of carrying a variant and discuss testing.

Is there a treatment that slows or stops CLN13 disease?

There is currently no approved treatment known to stop or slow the underlying disease. Care is individualized and may include neurology, physical therapy, symptom treatment, palliative care, and support for swallowing, mobility, and daily activities. The goals are to preserve function, comfort, dignity, and quality of life.

How can families prepare for changes caused by CLN13 disease?

Families can work with the care team to discuss the expected pace of change, home support, mobility and swallowing safety, and the person's goals for quality of life. Early palliative care can help with symptom relief, future planning, and decisions that respect the person's preferences. Plans should be revisited as needs change.

Curated prompts to bring to your next appointment.

1.How does the specific CTSF genetic result found in our case correlate with the symptoms we are currently seeing?
2.What multidisciplinary specialists—such as neurologists, physical therapists, and palliative care experts—should be prioritized in our care team right now?
3.Can you help us understand the expected pace of change so we can better plan for future support at home?
4.What are the safest and most effective ways to manage the behavioral shifts we are noticing, keeping medication risks in mind?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Key takeaways

CLN13 disease, also called Kufs disease type B, is a rare adult-onset form of neuronal ceroid lipofuscinosis, often called Batten disease.
Disease-causing CTSF variants can lead to cathepsin F deficiency and progressive buildup of cellular waste in brain cells.
Early behavioral, personality, judgment, and memory changes may be followed by parkinsonism, tremors, stiffness, ataxia, and swallowing or mobility difficulties; vision is often relatively preserved.
Molecular genetic testing is preferred to confirm CLN13 disease and clarify its autosomal recessive inheritance, while tissue biopsy may be inconclusive in adults.
There is no approved disease-modifying therapy; multidisciplinary symptom management, palliative care, and proactive planning support function, comfort, and quality of life.

References (15)

1
Clinical Heterogeneity of Neuronal Ceroid Lipofuscinosis Type 13: A Case Report and Systematic Review of Literature.
Ghayal NB, Roemer SF, Tipton PW, et al.
Neurology. Genetics 2025; (11(1)):e200227 doi:10.1212/NXG.0000000000200227.
PMID: 39720560
2
Novel frameshift CTSF mutation causing kufs disease type B mimicking frontotemporal dementia-parkinsonism.
Gultekin M, Tufekcioglu Z, Baydemir R
Neurocase 2022; (28(1)):107-109 doi:10.1080/13554794.2022.2038635.
PMID: 35139754
3
Mutated CTSF in adult-onset neuronal ceroid lipofuscinosis and FTD.
van der Zee J, Mariën P, Crols R, et al.
Neurology. Genetics 2016; (2(5)):e102 doi:10.1212/NXG.0000000000000102.
PMID: 27668283
4
Kufs disease due to mutation of CLN6: clinical, pathological and molecular genetic features.
Berkovic SF, Oliver KL, Canafoglia L, et al.
Brain : a journal of neurology 2019; (142(1)):59-69 doi:10.1093/brain/awy297.
PMID: 30561534
5
Brain imaging in Kufs disease type B: case reports.
Di Fabio R, Colonnese C, Santorelli FM, et al.
BMC neurology 2015; (15()):102 doi:10.1186/s12883-015-0357-6.
PMID: 26141065
6
Drug-refractory epilepsy due to a novel CLN5 mutation: A report of three patients from an Indian family.
Joy S, Agarwal A, Handique J, et al.
Seizure 2025; (124()):66-70 doi:10.1016/j.seizure.2024.11.017.
PMID: 39667065
7
Novel compound heterozygous mutations causing Kufs disease type B.
Wang C, Xu H, Yuan Y, et al.
The International journal of neuroscience 2018; (128(6)):573-576 doi:10.1080/00207454.2017.1403439.
PMID: 29120254
8
Adult-Onset Recessive Cerebellar Ataxia and Severe Multisystem Disease-Associated Genes: Hypomorphic Alleles and Clinical Interpretation Pitfalls.
Cipriano L, Petillo R, Priolo M, D'Ambrosio P
Genes 2026; (17(7)) doi:10.3390/genes17070758.
PMID: 42510798
9
Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients.
Mole SE, Schulz A, Badoe E, et al.
Orphanet journal of rare diseases 2021; (16(1)):185 doi:10.1186/s13023-021-01813-5.
PMID: 33882967
10
Management Strategies for CLN2 Disease.
Williams RE, Adams HR, Blohm M, et al.
Pediatric neurology 2017; (69()):102-112 doi:10.1016/j.pediatrneurol.2017.01.034.
PMID: 28335910
11
Management of CLN1 Disease: International Clinical Consensus.
Augustine EF, Adams HR, de Los Reyes E, et al.
Pediatric neurology 2021; (120()):38-51 doi:10.1016/j.pediatrneurol.2021.04.002.
PMID: 34000449
12
Case Report: The window that closed too soon: lessons from a late CLN2 diagnosis and death of a 9-year-old boy.
Bryzik A, Larysz D, Larysz P, et al.
Frontiers in genetics 2025; (16()):1622185 doi:10.3389/fgene.2025.1622185.
PMID: 40686560
13
Palliative Care in Amyotrophic Lateral Sclerosis.
Mercadante S, Al-Husinat L
Journal of pain and symptom management 2023; (66(4)):e485-e499 doi:10.1016/j.jpainsymman.2023.06.029.
PMID: 37380145
14
A novel two-day intervention reduces stress in caregivers of persons with dementia.
Spalding-Wilson KN, Guzmán-Vélez E, Angelica J, et al.
Alzheimer's & dementia (New York, N. Y.) 2018; (4()):450-460 doi:10.1016/j.trci.2018.08.004.
PMID: 30258974
15
Comparative efficacy of 11 non-pharmacological interventions on depression, anxiety, quality of life, and caregiver burden for informal caregivers of people with dementia: A systematic review and network meta-analysis.
Sun Y, Ji M, Leng M, et al.
International journal of nursing studies 2022; (129()):104204 doi:10.1016/j.ijnurstu.2022.104204.
PMID: 35247788

This page is for informational purposes only and does not constitute medical advice. A neurologist and genetics team should interpret CTSF results and help tailor supportive care to the person's needs.

Get notified when new evidence is published on CLN13 disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents